$INNMF News
Last published 3mo ago
- 3mo agoINNMFAmplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung CancerGlobeNewswireHIGHLIGHTS Amplia has executed a Clinical Trial Collaboration & Supply Agreement (CTCSA) with Eli Lilly & Company, to evaluate the Company’s investigational FAK inhibitor narmafotinib in combination with
- 3mo agoINNMFScientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now OnlineGlobeNewswireHIGHLIGHTS A manuscript describing comprehensive preclinical studies of narmafotinib in models of pancreatic cancer is now available online.The findings provide further evidence of narmafotinib's ability to target
- 4mo agoINNMFAmplia Announces Publication of New FAK Inhibitor Patent ApplicationGlobeNewswireHIGHLIGHTS New patent application published covering chemically novel FAK inhibitors discovered by AmpliaApplication expands Amplia’s intellectual property portfolio supporting its FAK inhibitor programIf granted,
- 4mo agoINNMFAmplia Announces Appointment of Brett Carter to BoardGlobeNewswireMelbourne, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited ((ASX:ATX, OTCQB:INNMF), ("Amplia" or the "Company"), is pleased to announce the appointment of Mr Brett Carter to
- 4mo agoINNMFAmplia Announces Changes to Board’s Leadership RolesGlobeNewswireMelbourne, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited ((ASX:ATX, OTCQB:INNMF), ("Amplia" or the "Company"), announces Board changes further to a Board renewal and
- 4mo agoINNMFFollowing Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic CancerGlobeNewswireMelbourne, Australia, June 22, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited ((ASX:ATX, OTCQB:INNMF), ("Amplia" or the "Company") provides a letter to shareholders from CEO and Managing Director
- 5mo agoINNMFAmplia Therapeutics Launches First Stage of Registration-Enabling Trial of NarmafotinibGlobeNewswireHIGHLIGHTS New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational studyFocus on investigating new, daily dosing of narmafotinib in combination with standard
- 6mo agoINNMFAmplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer StudyGlobeNewswireMelbourne, Australia, May 08, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Amplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with standard-of-care
- 6mo agoINNMFAccent Trial Mature Data Presented at International ConferenceGlobeNewswireHIGHLIGHTS Mature data from Amplia's ACCENT trial in pancreatic cancer is being presented at the prestigious American Association of Cancer Research (AACR) annual meetingThe ACCENT trial investigates the combination of
- 7mo agoINNMFAmplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer TrialGlobeNewswireHIGHLIGHTS Formal centralized and independent analysis of the clinical response data from the ACCENT trial has been undertaken and updated analysis provided to the CompanyThe data confirm that five (5) patients have
- 8mo agoINNMFPoster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer ModelsGlobeNewswireHIGHLIGHTS Amplia's lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conferenceData showing narmafotinib activity in preclinical models of pancreatic
- 9mo agoINNMFAmplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer TrialGlobeNewswireMelbourne, Australia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Two US-based sites have completed trial initiation activities for the AMPLICITY trial in pancreatic cancer These sites join the two Australian sites
- 9mo agoINNMFAmplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025GlobeNewswireMelbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial Success: The ACCENT trial, testing narmafotinib with gemcitabine and Abraxane®, continues to demonstrate that
- 9mo agoINNMFNARMAFOTINIB Large-Scale Manufactre CompleteGlobeNewswireSuccessful completion of the first large-scale manufacture of narmafotinib which produced approx. 13 kg of drug Successful transition of process and production from an R&D facility to a commercial manufacturing
- 10mo agoINNMFACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUMGlobeNewswireHIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal Cancer SymposiumUpdated data analysis continues to show that Narmafotinib
- 10mo agoINNMFAmplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers SymposiumGlobeNewswireMelbourne, Australia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited ((ASX:ATX, OTCQB:INNMF) ("Amplia" or the "Company") is pleased to announce that the Company's CMO Dr Jason Lickliter will present a
- 10mo agoINNMFAmplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS InhibitorsGlobeNewswireHIGHLIGHTS The preclinical research collaboration with specialist drug screening company Next & Bio has been extendedThe collaboration explores the effect of Amplia's FAK inhibitors in combination with experimental
- 11mo agoINNMFAdditional Confirmed Response Reported as Part of Amplia Investor PresentationGlobeNewswireHIGHLIGHTS An additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate to 35%Updated data to be presented at the Life Sciences Virtual Investor
- 11mo agoBICXDTCFFECHQFGNVR+4Life Sciences Virtual Investor Forum Agenda Announced for December 11thGlobeNewswireNEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Life Sciences Virtual Investor Forum to be held December 11th.
- 11mo agoINNMFAmplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11thGlobeNewswireMELBOURNE, Vic, Australia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (OTCQB:INNMF), based in Melbourne, Australia and focused on developing new therapies for hard to treat cancers, today announced
- 11mo agoINNMFKey Narmafotinib Patent Granted in the U.S.GlobeNewswireHighlights The Company has received a Certificate of Grant from the US Patent and Trademark Office for a key patent for the FAK inhibitor narmafotinibThe patent extends protection for narmafotinib to at least 2040
- 1y agoACUTDRMAHMTXFINM+4Life Sciences Virtual Investor Forum: Presentations Now Available for Online ViewingGlobeNewswireNEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held